Journal
BIOANALYSIS
Volume 12, Issue 13, Pages 919-935Publisher
Newlands Press Ltd
DOI: 10.4155/bio-2020-0063
Keywords
biomarkers; COVID-19; DBS; microsampling; patient-centric sampling; proteomics; sampling device; SomaScan; TAP; VAMS
Funding
- Novartis
Ask authors/readers for more resources
Aim: Evaluation of a novel microsampling device for its use in clinical sample collection and biomarker analysis. Methodology: Matching samples were collected from 16 healthy donors (ten females, six males; age 42 +/- 20) via K2EDTA touch activated phlebotomy (TAP) device and phlebotomy. The protein profile differences between sampling groups was evaluated using aptamer-based proteomic assay SomaScan and selected ELISA. Conclusion: Somascan signal concordance between phlebotomy- and TAP-generated samples was studied and comparability of protein abundances between these blood sample collection methods was demonstrated. Statistically significant correlation in selected ELISA assays also confirmed the TAP device applicability to the quantitative analysis of protein biomarkers in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available